Inogen マネジメント

マネジメント基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

Kevin R. Smith

最高経営責任者

US$2.4m

報酬総額

CEO給与比率	4.4%
CEO在任期間	less than a year
CEOの所有権	n/a
経営陣の平均在職期間	less than a year
取締役会の平均在任期間	2.7yrs

経営陣の近況

Recent updates

CEO報酬分析

Inogen の収益と比較して、Kevin R. Smith の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$53m
Jun 30 2024	n/a	n/a	-US$92m
Mar 31 2024	n/a	n/a	-US$97m
Dec 31 2023	US$2m	US$108k	-US$102m

報酬と市場: Kevin R.の総報酬 ($USD 2.45M ) は、 German市場 ($USD 850.62K ) の同規模の企業の平均を上回っています。

報酬と収益: Kevin R.の報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Kevin R. Smith (53 yo)

less than a year

在職期間

US$2,448,754

報酬

Mr. Kevin R. M. Smith serves as President, Chief Executive Officer and Director at Inogen Inc. since November 13, 2023. He served as Director at OncoSec Medical Incorporated since February 7, 2020 until Ju...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Kevin R. Smith	President	less than a year	US$2.45m	データなし
Michael Bourque	Executive VP	less than a year	データなし	データなし
Philip Corrin	Senior Vice President of Operations & Supply Chain	1.8yrs	データなし	データなし
Kevin Smith	General Counsel & Executive VP of Business Development	less than a year	データなし	データなし
Jennifer Boyer	Executive VP & Chief Human Resources Officer	2.5yrs	データなし	データなし
Grgoire Ramade	Executive VP & Chief Commercial Officer	less than a year	データなし	データなし
Krishna Jhaveri	Chief Medical Officer	less than a year	データなし	データなし
Paul Andreassi	Senior Vice President of Quality & Regulatory Affairs	less than a year	データなし	データなし
Adrien Mithalal	Senior Vice President of Research & Development	less than a year	データなし	データなし

0.8yrs

平均在職期間

54yo

平均年齢

経験豊富な経営陣: 6IOの経営陣は経験豊富とはみなされません ( 0.8年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Kevin R. Smith	President	less than a year	US$2.45m	データなし
Richard Casaburi	Member of Advisory Board	no data	データなし	データなし
Jeffrey Kupperman	Member of Advisory Board	no data	データなし	データなし
Paul Selecky	Member of Advisory Board	no data	データなし	データなし
Mary Ladone	Independent Director	2.7yrs	US$242.50k	0.10% € 233.0k
Kevin King	Independent Director	2.7yrs	US$250.00k	0.10% € 233.0k
Neil MacIntyre	Member of Advisory Board	no data	データなし	データなし
Elizabeth Mora	Independent Board Chairperson	3.5yrs	US$315.00k	0.11% € 254.9k
Robert Chatburn	Member of Advisory Board	no data	データなし	データなし
Thomas West	Independent Director	1.6yrs	US$266.24k	0.079% € 179.5k
Heather Rider	Independent Director	10.3yrs	US$242.50k	0.16% € 360.1k
Glenn Boehnlein	Independent Director	2.7yrs	US$250.00k	0.10% € 233.0k

2.7yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: 6IOの取締役会は経験豊富ではない ( 2.7年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Inogen マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Inogen, Inc. Appoints Kevin P. Smith as General Counsel and Executive Vice President, Business Development, Effective July 22, 2024

Executive VP recently sold €79k worth of stock

Inogen, Inc., Annual General Meeting, Jun 05, 2024

Inogen, Inc. Announces CFO Changes, Effective March 4, 2024

Inogen, Inc. Appoints Grgoire Ramade to Serve as Chief Commercial Officer

Inogen, Inc. Announces Separation Agreement with Nabil Shabshab

Recent updates

New minor risk - Shareholder dilution

Third quarter 2024 earnings released: US$0.25 loss per share (vs US$1.97 loss in 3Q 2023)

Inogen, Inc. Provides Revenue Guidance for the Full Year 2024

Inogen, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Inogen Launches Rove 4 Portable Oxygen Concentrator, Delivering the Highest Oxygen Output in the Lightest Weight 4-Setting Poc

New minor risk - Shareholder dilution

New major risk - Share price stability

Second quarter 2024 earnings released: US$0.24 loss per share (vs US$0.42 loss in 2Q 2023)

Inogen, Inc. Provides Revenue Guidance for the Full Year 2024

Inogen, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Inogen, Inc. Appoints Kevin P. Smith as General Counsel and Executive Vice President, Business Development, Effective July 22, 2024

Inogen, Inc. Announces Publication of Study Demonstrating the Association of Portable Oxygen Therapy with Decreased Survival and Increased Cost-Effectiveness Ratio

Executive VP recently sold €79k worth of stock

First quarter 2024 earnings released: US$0.62 loss per share (vs US$0.88 loss in 1Q 2023)

Inogen, Inc. Provides Revenue Guidance for the Second Quarter of 2024

New minor risk - Shareholder dilution

Inogen, Inc., Annual General Meeting, Jun 05, 2024

Inogen, Inc. to Report Q1, 2024 Results on May 07, 2024

Inogen, Inc. Provides Earnings Guidance for the First Quarter 2024

Full year 2023 earnings released: US$4.42 loss per share (vs US$3.67 loss in FY 2022)

Inogen, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Inogen, Inc. Announces CFO Changes, Effective March 4, 2024

Inogen, Inc. Appoints Grgoire Ramade to Serve as Chief Commercial Officer

Inogen, Inc. Announces Separation Agreement with Nabil Shabshab

Inogen, Inc. Announces Separation Agreement with Nabil Shabshab

Inogen Announces CEO Changes

Third quarter 2023 earnings released: US$1.97 loss per share (vs US$0.41 loss in 3Q 2022)

New minor risk - Market cap size

Inogen, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Inogen, Inc. Announces Executive Changes

Second quarter 2023 earnings released: US$0.42 loss per share (vs US$0.15 loss in 2Q 2022)

Inogen, Inc. Announces the Introduction of the Rove 6(Tm) Portable Oxygen Concentrators in the United States

Inogen, Inc. Announces Board Changes

Inogen, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Inogen, Inc. Reiterates Earnings Guidance for the Year 2023

First quarter 2023 earnings released: US$0.88 loss per share (vs US$0.63 loss in 1Q 2022)

Full year 2022 earnings released: US$3.67 loss per share (vs US$0.28 loss in FY 2021)

Inogen, Inc. Announces Bart Sanford to Step Down as Executive Vice President, Operations Effective on or Before March 1, 2023

Inogen, Inc. to Report Q4, 2022 Results on Feb 23, 2023

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.41 loss per share (vs US$0.54 profit in 3Q 2021)

Inogen, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Inogen, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Second quarter 2022 earnings released: US$0.15 loss per share (vs US$0.23 profit in 2Q 2021)

High number of new and inexperienced directors

Inogen, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Inogen, Inc.(NasdaqGS:INGN) dropped from Russell 2000 Growth-Defensive Index

Inogen, Inc. Names Agnes Lee as Senior Vice President of Investor Relations and Strategic Planning, Effective May 23, 2022

Inogen, Inc. Provides Earnings Guidance for the Second Quarter of 2022

High number of new and inexperienced directors

Inogen, Inc., Annual General Meeting, Jun 08, 2022

Inogen, Inc. Announces Management Changes

Inogen, Inc. to Report Q1, 2022 Results on May 05, 2022

High number of new and inexperienced directors

Inogen, Inc. Executive Changes

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Loren McFarland Not to Stand for Re-Election as Director of Inogen, Inc

Inogen, Inc. Provides Preliminary Unaudited Revenue Guidance for the Three-Month and Twelve-Month Periods Ended December 31, 2021

Third quarter 2021 earnings released: EPS US$0.54 (vs US$0.077 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS US$0.23 (vs US$0.12 in 2Q 2020)

Inogen, Inc.(NasdaqGS:INGN) dropped from Russell 3000E Value Index

Inogen, Inc. Unable to Provide Guidance for the Full Year 2021

Inogen Announces Board Changes

Inogen, Inc. Unables to Provide Guidance for the Full Year 2021

Inogen, Inc Announces Management Changes

Independent Director has left the company

Inogen, Inc. to Report Q4, 2020 Results on Feb 24, 2021

New 90-day high: €42.00

Inogen, Inc. Announces Change of Chief Executive Officers

マネジメント基準チェック /04